HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix.
A series of 10 normal cervix epithelia, 38 condylomas, 17 CIN (cervical intraepithelial neoplasm) I/II (low-grade CIN), 10 CIN III (high-grade CIN), 27 squamous cell carcinomas and 7 adenocarcinomas of the cervix were studied in paraffin-embedded sections for the expression of MHC class I antigens, using antibodies against HLA antigens and the immunoperoxidase technique. A PCR technique was also used to evaluate the presence of HPV-16 DNA. All samples from normal tissue, benign, premalignant and CIN III lesions expressed HLA class I antigens. However, 15% of the invasive carcinomas completely lacked HLA-B and HLA-C antigen expression, 20% presented a heterogeneous pattern and 2 cases lacked HLA-B and HLA-C heavy chain but retained beta 2-microglobulin. MHC class I antigen expression on tumors was compared with clinical-pathological parameters. The absence of expression of HLA class I molecules was significantly associated with the Glanz histoprognostic index of malignancy. HPV-16 sequences were detected in 60% of the condylomas, 88% of the CIN I/II, 80% of the CIN III and 82% of the cervical carcinomas. Eight-six per cent of the tumors expressing HLA class I antigen presented HPV-16, whereas only 40% of the nonexpressing tumors did. Our results lead us to the following conclusions: a) HLA class I losses occurred when the tumor became invasive, and in tumors of a more aggressive histological type; b) The presence of HPV-16 was associated with tumors expressing HLA class I antigens.
Servicio de Análisis Clínicos e Inmunología, Hospital Virgen de las Nieves, Granada, Spain.
L M
LM
Torres
T
T
Cabrera
A
A
Concha
M R
MR
Oliva
F
F
Ruiz-Cabello
F
F
Garrido
D000230:Adenocarcinoma / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D002278:Carcinoma in Situ / Q000276:immunology / Q000382:microbiology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D002584:Cervix Uteri / Q000276:immunology / Q000382:microbiology*; D003218:Condylomata Acuminata / Q000276:immunology / Q000382:microbiology*; D015344:DNA Probes, HPV; D004279:DNA, Viral / Q000032:analysis*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006680:HLA Antigens / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D009361:Neoplasm Invasiveness; D027383:Papillomaviridae / Q000145:classification / Q000302:isolation & purification* / Q000472:pathogenicity; D016133:Polymerase Chain Reaction; D011230:Precancerous Conditions / Q000276:immunology / Q000382:microbiology*; D014412:Tumor Virus Infections / Q000276:immunology* / Q000382:microbiology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000382:microbiology* / Q000473:pathology
D015344:DNA Probes, HPV; D004279:DNA, Viral; D006680:HLA Antigens